Bolt Biotherapeutics (BOLT)
(Delayed Data from NSDQ)
$1.11 USD
-0.05 (-4.31%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $1.16 +0.05 (4.50%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BOLT 1.11 -0.05(-4.31%)
Will BOLT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BOLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BOLT
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates
BOLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates
Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?
Other News for BOLT
Bolt Metals Completes $231K Private Placement
12 Health Care Stocks Moving In Wednesday's After-Market Session
Bolt Biotherapeutics: A Strong Buy on Clinical Progress and Financial Stability
Bolt Biotherapeutics’ Promising Trajectory in Immuno-Oncology: A Strong Buy Recommendation
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)